At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pharmacological Treatment of Generalized Anxiety Disorder in the Elderly
In Brief
A Phase 4 clinical trial evaluating sertraline 50 mg daily, sertraline 100 mg daily, and 1 other intervention for Generalized Anxiety Disorder. Completed, enrolled 42 participants across 3 sites.
Detailed Summary
Generalized anxiety disorder (GAD) is a very common disorder in the geriatric population with prevalence rates reaching 7% and even higher rates of 8% among elderly veterans. However, despite such high prevalence treating clinicians are presently forced to address treatment issues in this population without the guidance of scientific data. This proposal aims to begin to address this void. In light of emerging information regarding efficacy of the newer anti anxiety agents, specifically the selective serotonin reuptake inhibitors (SSRIs), in the treatment of young adult GAD patients it is time to prospectively evaluate the safety and efficacy of these medications in the treatment of elderly GAD patients. Therefore, this study will examine the effects and safety of the SSRI sertraline at different doses (50mg and 100mg per day) for older patients with GAD.
Study Details
Timeline
Interventions
50 mg daily
100 mg daily
50mg or 100mg matching placebo